Why is Twist Bioscience stock sliding today?

Twist Bioscience shares fell 11.6% to $126.03 after short-seller The Bear Cave argued the company’s valuation exceeds what its core business fundamentals support, and characterized its Anthropic relationship as contract services rather than a strategic partnership. The report also highlighted more than $93 million in insider share sales over the past three months; Twist’s fiscal Q4 2026 earnings release is scheduled for November 12. The decline coincided with a broad selloff, with the Nasdaq down roughly 4.5%, the S&P 500 off 3.3% and the Dow lower by 2.5%.

Analysis

The key exposure is not simply whether Twist’s core tools business is growing; it is whether investors are assigning durable strategic value to an AI relationship that may prove economically closer to ordinary contract work. If the relationship does not translate into repeatable, material revenue or differentiated access to customers, the valuation premium can unwind even while the underlying business performs adequately. That also raises a read-through risk for other synthetic-biology vendors whose valuations rely on AI optionality rather than disclosed, monetizable demand.

Near term, the November 12 results are a binary catalyst in a poor tape for long-duration growth stocks. A short-seller report and insider sales can amplify positioning pressure, but neither establishes deteriorating operations; a squeeze or a credible company clarification could reverse the move quickly. Over 1–3 months, focus on guidance, order trends, gross-margin direction, and any quantified disclosure about the Anthropic relationship. Over 6–18 months, the structural question is whether cheaper or more established alternatives constrain pricing and prevent AI-related demand from becoming a meaningful growth engine.

Contrarian angle: the selloff may be pricing a challenged narrative, not a demonstrated earnings impairment. The bear case is stronger if management cannot substantiate the commercial significance of the AI work; it is weaker if results show broad-based core demand and the relationship is clearly incremental. No valuation or peer data are supplied, so the report’s relative-multiple claim should be independently checked rather than treated as established.

Key Decisions for Investors

• Avoid adding to TWST ahead of earnings; treat the release as the next information event rather than extrapolating the short-seller report into an operating forecast.
• For a bearish expression, consider a small, defined-risk TWST put spread only if post-selloff implied volatility and pricing still offer acceptable risk/reward. Avoid an unhedged short into a binary event and squeeze risk.
• After results, reassess against specific evidence: revenue/order trends and guidance, margin trajectory, and management’s quantified description of the Anthropic work. A material guidance reduction or failure to clarify commercial scale supports the downside thesis; stable core metrics plus credible incremental demand would weaken it.
• Monitor for reversal signals over the next 1–3 months: a company clarification, earnings-driven gap recovery, or broad reversal in high-multiple growth stocks. These could invalidate a tactical short even if the longer-term valuation debate remains.